TG Therapeutics, Inc.

Total Valuation

TG Therapeutics, Inc. carries a market capitalization of 8.81B, placing it among publicly traded companies globally. Its enterprise value stands at 8.61B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

TG Therapeutics, Inc. currently has 153.08M shares outstanding.

Valuation Ratios

TG Therapeutics, Inc. trades at a trailing price-to-earnings ratio of 17.88. The price-to-sales ratio is 9.87, and the price-to-book ratio stands at 13.92.

Enterprise Valuation

On an enterprise value basis, TG Therapeutics, Inc. trades at an EV/EBITDA multiple of 63.03 and an EV/FCF ratio of 47.51. The EV/Sales ratio of 10.77 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 63.17 provides insight into valuation relative to core operating earnings.

Financial Position

TG Therapeutics, Inc. maintains a current ratio of 4.27, meaning it holds 4.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 124.89, indicating elevated leverage, while an interest coverage ratio of 3.64 demonstrates adequate ability to service its debt obligations.

Financial Efficiency

Taxes

Over the trailing twelve months, TG Therapeutics, Inc. has paid -339.89M in income taxes, reflecting an effective tax rate of 75.76.

Stock Price Statistics

TG Therapeutics, Inc.'s stock has gained approximately 62.43999% over the past 52 weeks. The 50-day moving average sits at 53.53, while the 200-day moving average is 40.45.

Income Statement

Over the trailing twelve months, TG Therapeutics, Inc. generated 799.54M in revenue and converted that into 441.49M in net income, yielding earnings per share of 2.77. EBITDA reached 136.63M, while operating income came in at 136.33M.

Balance Sheet

TG Therapeutics, Inc. holds 552.25M in cash and equivalents against 754.44M in total debt, resulting in a net debt position of 262.81M. Total book value stands at 604.08M, with working capital of 877.19M providing operational flexibility.

Cash Flow

TG Therapeutics, Inc. produced 17.88M in operating cash flow over the past twelve months. After subtracting -491,000.00 in capital expenditures, free cash flow totaled 17.39M - equivalent to 0.12 per share.

Margins

TG Therapeutics, Inc. operates with a gross margin of 82.37, reflecting its pricing power and cost economics. The operating margin of 17.05 and net profit margin of 55.22 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

TG Therapeutics, Inc.'s most recent stock split took place on April 30, 2012 with a 225:4 split ratio.

Scores

TG Therapeutics, Inc. posts an Altman Z-Score of 5.38, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.